Latest news with #dentaltechnology
Globe and Mail
6 days ago
- Business
- Globe and Mail
Sonendo, Inc. Reports Second Quarter 2025 Financial Results and Reaffirms Financial Guidance
Sonendo, Inc. ('Sonendo' or the 'Company'), a leading dental technology company and developer of the GentleWave® System, today reported select financial results for the three-months ended June 30, 2025 and reaffirmed 2025 financial guidance. Select Second Quarter Financial Results Generated $7.4 million of total revenue for the second quarter of 2025, an 11% decline compared to the prior year period, which was expected and driven entirely by lower console sales through a smaller and more cost effective sales team; Reported an increase in gross margin to 41% for the second quarter of 2025, up 320 basis points compared to the prior year period; Reported a $3.6 million reduction in loss from continuing operations compared to the prior period, to $3.9 million for the second quarter of 2025; Drove a 47% year-over-year improvement in Adjusted EBITDA loss to $3.0 million for the second quarter of 2025, driven by focused operational efficiencies; Significantly reduced free cash flow burn to $2.6 million, a 61% reduction compared to the prior year period. 'We are pleased by the continued progress we have made in generating increasing operating leverage in the business, as demonstrated in our second quarter 2025 financial and operational results,' said Bjarne Bergheim, President and Chief Executive Officer of Sonendo. 'In particular, we are selling consoles much more efficiently and with a focus on driving higher procedure instrument utilization. We are also focusing the commercial team's efforts on being more responsive to the clinical needs of our customers and their patients. We recently improved the liquidity profile of the Company in a meaningful way, and we remain steadfastly committed to operational excellence and to position Sonendo for robust, long-term and profitable growth.' As of June 30, 2025, the Company's cash, cash equivalents and short-term investments totaled $9.3 million, and there was $14.2 million of principal outstanding under the Company's credit facility. Financial Guidance The Company is reaffirming the 2025 financial guidance it previously provided, which reflects management's latest expectations and is provided below. (1) See additional information included in the Company's Form 8-K filed with the Securities and Exchange Commission on November 12, 2024 for additional information about the Company's use of these non-GAAP financial measures. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices. For more information about Sonendo and the GentleWave System, please visit To find a GentleWave doctor in your area, please visit Forward-Looking Statements This news release includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the Company's expectations regarding 2025 financial performance, including (among other things) revenue, gross margin, adjusted EBITDA and free cash flow; and the Company's ability to achieve robust, long-term and profitable growth. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions; speak only as of the date they are made; and, as a result, are subject to risks and uncertainties that may change at any time. Factors that could cause the Company's actual results to differ materially from these forward-looking statements are described in detail in the 'Risk Factors' section of the Company's Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on March 26, 2025. Such filings are available at The Company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
National Post
09-07-2025
- Health
- National Post
LuxCreo Unveils Integration with Alliedstar Intraoral Scanners, Enhancing Scan-to-Design Workflow
Article content Sorry, your browser doesn't support embedded videos. Article content CHICAGO — LuxCreo, a global leader in personalized medical and dental devices, announced today their integration with Alliedstar, a pioneer in the field of intraoral scanners. This integration enables LuxCreo users to seamlessly transfer scans from Alliedstar's AS Connect software directly into LuxDesign, LuxCreo's appliance design platform. Article content 'By connecting Alliedstar's precision scanning with our LuxDesign platform, we are giving dental professionals a seamless scan-to-design workflow to make same-day dentistry an accessible reality.' Article content As part of this integration, a new 'LuxDesign' button has been embedded within the AS Connect interface, allowing dental professionals to send their scans to LuxDesign with a single click—eliminating manual uploads, saving time, and reducing the risk of data errors. This streamlined process enhances the creation of a wide range of personalized medical and dental devices, including retainers, aligners, nightguards, restorative models, and more. Article content Louise Lu, Co-Founder and Head of Product at LuxCreo, emphasized the importance of the partnership saying, 'By connecting Alliedstar's precision scanning with our LuxDesign platform, we are giving dental professionals a seamless scan-to-design workflow to make same-day dentistry an accessible reality.' Article content This partnership marks a significant step in unifying digital dental workflows, empowering clinics and labs with a faster, more reliable, and more user-friendly solution for delivering patient care. Article content By connecting Alliedstar's precision intraoral scanning technology with LuxCreo's streamlined 3D printing and design tools, the integration supports same-day dentistry and scalable in-office production, ensuring every practice starts with an essential foundation to each appliance: An accurate scan. Article content About LuxCreo: Article content LuxCreo is the leading platform for personalized medical and dental devices, dedicated to empowering doctors to transform patient care through innovation, speed, and customer success. We empower doctors to design, create, and deliver same-day treatments that enhance smiles, health, and well-being for a wider number of patients. Article content Our unique ecosystem supports dental and medical professionals with onsite, scalable solutions and flexible production with laboratory design and production services. LuxCreo helps doctors grow their practices and improve patient care by delivering more customized and effective treatments with convenience and precision. For more information, visit Article content About Alliedstar: Article content Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Article content
Associated Press
04-06-2025
- Business
- Associated Press
Sonendo, Inc. Reports First Quarter 2025 Financial Results and Issues Financial Guidance
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Jun 4, 2025-- Sonendo, Inc. ('Sonendo' or the 'Company') (OTC Pink: SONX), a leading dental technology company and developer of the GentleWave® System, today reported select financial results for the first quarter ended March 31, 2025 and issued short and long-term financial guidance. Recent Highlights 'We are pleased that our lender and the new and existing investors who participated in the private placement have recognized the meaningful success we have achieved in restructuring the business and increasing revenue while significantly reducing operating expenses and free cash flow burn, as demonstrated in our first quarter 2025 financial and operational results,' said Bjarne Bergheim, President and Chief Executive Officer of Sonendo. 'We have significantly improved the liquidity profile of the Company, and we expect to deliver additional gross margin expansion and further reductions in operating losses and free cash flow burn in 2025. We remain steadfastly committed to operational excellence and to position Sonendo for robust, long-term and profitable growth.' As of March 31, 2025, the Company's cash, cash equivalents and short-term investments totaled $7.2 million, which does not include the $4.7 million in estimated net proceeds the Company received in the private placement, and there was $14.2 million of principal outstanding under its credit facility. Financial Guidance The Company is providing the following short and long-term financial guidance, which reflects management's latest expectations. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices. For more information about Sonendo and the GentleWave System, please visit To find a GentleWave doctor in your area, please visit Forward Looking Statements This news release includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the Company's expectations regarding short- and long-term financial performance, including (among other things) GAAP gross margin, adjusted EBITDA and free cash flow; the Company's expectations to deliver additional gross margin expansion and further reduce operating losses and free cash flow burn in 2025; and the Company's ability to achieve robust, long-term and profitable growth. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions; speak only as of the date they are made; and, as a result, are subject to risks and uncertainties that may change at any time. Factors that could cause the Company's actual results to differ materially from these forward-looking statements are described in detail in the 'Risk Factors' section of the Company's Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on March 26, 2025. Such filings are available at The Company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. View source version on CONTACT: Investor Contact: [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: HEALTH TECHNOLOGY HEALTH DENTAL MEDICAL DEVICES SOURCE: Sonendo Copyright Business Wire 2025. PUB: 06/04/2025 06:30 AM/DISC: 06/04/2025 06:29 AM
